Medicure Inc
NGQ1
Company Profile
Business description
Medicure Inc is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.
Contact
2 - 1250 Waverley Street
WinnipegMBR3T 6C6
CANT: +1 204 487-7412
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
23
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,129.60 | 22.10 | -0.24% |
| CAC 40 | 8,347.20 | 0.00 | 0.00% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 26,940.41 | 91.94 | 0.34% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,360.87 | 811.71 | 1.52% |
| NZX 50 Index | 13,695.33 | 39.28 | 0.29% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,800.30 | 21.50 | -0.24% |
| SSE Composite Index | 4,158.15 | 19.39 | 0.47% |